-
1دورية أكاديمية
المؤلفون: Jucevičiūtė, Neringa, Mikužis, Paulius, Balnytė, Renata
المصدر: BMC neurology, London : BioMed Central, 2019, vol. 19, no. 1, p. 1-8 ; ISSN 1471-2377
مصطلحات موضوعية: Stroke, drug therapy, Brain ischemia, Fibrinolytic agents, therapeutic use, administration&dosage, Administration, intravenous, adverse effects, Intracranial hemorrhages, chemically induced, Risk factors, info:eu-repo/classification/udc/616.831-005.1
الوصف: BACKGROUND: Immune cells are involved in all stages of acute ischaemic stroke (AIS) and possess both neuroprotective and neurodamaging properties. It has been suggested that immune system activation after stroke may be associated with the development of haemorrhagic transformation (HT), which is the main complication limiting the clinical use of intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) for AIS. The purpose of our study was to analyse the association between absolute eosinophil count (AEC) at admission and the occurrence of HT after intravenous rtPA therapy for AIS. METHODS: In this retrospective study we enrolled AIS patients who were treated with rtPA within 4.5 h of symptom onset. Baseline stroke severity was evaluated using the National Institutes of Health Stroke Scale (NIHSS). Patients underwent head computed tomography scans at admission which were repeated 24 h after treatment with rtPA or promptly in case of clinical deterioration. HT was defined as blood at any site in the brain on follow-up head computed tomography scans. Spearman's rank correlation test was used to analyse the correlation between AEC and NIHSS scores. The optimal AEC cut-off value for predicting HT was calculated using the area under the receiver operating characteristic curve. Multiple logistic regression was used to determine the association between AEC included as a binary variable and the incidence of HT. RESULTS: The data of 201 patients was analysed (59.7% females; median age 77 years); 23 (11.4%) of them developed HT. The median of AEC was 62.5% greater in the non-HT group compared to the HT group (0.13 x 10(9)/l and 0.08 x 10(9)/l, respectively, p = 0.026). No correlation was found between AEC and baseline NIHSS scores (r = 0.061, p = 0.393). AEC >/= 0.11 x 10(9)/l predicted the occurrence of HT with 69.6% sensitivity and 60.7% specificity. AEC >/= 0.11 x 10(9)/l was independently associated with a 78% reduction [.].
وصف الملف: application/pdf
العلاقة: http://lsmu.oai.elaba.lt/documents/39007051.pdfTest; http://lsmu.lvb.lt/LSMU:ELABAPDB39007051&prefLang=en_USTest
-
2دورية أكاديمية
المصدر: Medicina, Kaunas; Basel : LSMU, MDPI AG, 2019, vol. 55, no. 2, 25, p. 1-14 ; ISSN 1010-660X ; eISSN 1648-9144
مصطلحات موضوعية: Head and neck neoplasms, drug therapy, radiotherapy, Antineoplastic agents, adverse effects, adverse effcts, Stomatitis, chemically induced, prevention&control, info:eu-repo/classification/udc/616.31-002
الوصف: Background and objectives: Oral mucositis is one of the main adverse events of cancer treatment with chemotherapy or radiation therapy. It presents as erythema, atrophy or/and ulceration of oral mucosa. It occurs in almost all patients, who receive radiation therapy of the head and neck area and from 20% to 80% of patients who receive chemotherapy. There are few clinical trials in the literature proving any kind of treatment or prevention methods to be effective. Therefore, the aim of this study is to perform systematic review of literature and examine the most effective treatment and prevention methods for chemotherapy or/and radiotherapy induced oral mucositis. Materials and methods: Clinical human trials, published from 1 January 2007 to 31 December 2017 in English, were included in this systematic review of literature. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) protocol was followed while planning, providing objectives, selecting studies and analyzing data for this systematic review. “MEDLINE” and “PubMed Central” databases were used to search eligible clinical trials. Clinical trials researching medication, oral hygiene, cryotherapy or laser therapy efficiency in treatment or/and prevention of oral mucositis were included in this systematic review. Results: Results of the studies used in this systematic review of literature showed that laser therapy, cryotherapy, professional oral hygiene, antimicrobial agents, Royal jelly, L. brevis lozenges, Zync supplementation and Benzydamine are the best treatment or/and prevention methods for oral mucositis. Conclusions: Palifermin, Chlorhexidine, Smecta, Actovegin, Kangfuxin, L. brevis lozenges, Royal jelly, Zync supplement, Benzydamine, cryotherapy, laser therapy and professional oral hygiene may be used in oral mucositis treatment and prevention.
وصف الملف: application/pdf
العلاقة: http://lsmu.oai.elaba.lt/documents/33930437.pdfTest; http://lsmu.lvb.lt/LSMU:ELABAPDB33930437&prefLang=en_USTest
-
3مؤتمر
المؤلفون: Jucevičiūtė, Neringa, Mikužis, Paulius, Balnytė, Renata
المصدر: Mokslo ir inovacijų savaitė 2019: sveikata visiems : 70-oji jaunųjų mokslininkų ir tyrėjų konferencija : tezių knyga 2019 : [2019] balandžio 8-12 d. Kaunas, Lietuva / Lietuvos sveikatos mokslų universiteto studentų mokslinė draugija ; Sudarė: Mindaugas Stonis, Kaunas : Lietuvos sveikatos mokslų universiteto studentų mokslinė draugija, 2019, p. 178-180
-
4دورية أكاديمية
المؤلفون: Šiupšinskienė, Nora, Tverskis, Žygimantas
المصدر: Otorinolaringologijos aktualijos, Kaunas : Medicinos spaudos namai, 2020, Nr. 1(25), p. 12-14 ; ISSN 1822-6795
-
5دورية أكاديمية
المؤلفون: Rusilas, Henrikas, Balčiūnaitė, Aušra, Žilinskas, Juozas
المصدر: Stomatologija, Kaunas : Viešoji įstaiga "Odontologijos studija", 2020, vol. 22, no. 1, p. 22-27 ; ISSN 1392-8589
مصطلحات موضوعية: Bisphosphonate-associated osteonecrosis of the jaw, therapy, Jaw diseases, chemically induced, Osteonecrosis, Platelet-rich plasma, info:eu-repo/classification/udc/617.52
الوصف: Background. Medication related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction occurring as a progressive bone destruction in the maxillofacial region. MRONJ is usually initiated after oral surgery procedures, however periodontal disease and other chronic infl ammations are also risk factors. There is no clear treatment protocol for management of MRONJ, for this reason autologous platelet concentrates (APC) have been introduced to enhance the healing process. Aim. To evaluate the effectiveness of APCs in treatment of MRONJ. Methods. A systematic literature review was performed according to PRISMA guidelines in MEDLINE (PubMed) and Google Scholar databases. Only no older than 5 years, in vivo studies in English with follow-up until condition totally resolves were included. Results. A total of 2683 publications were identifi ed out of which only 7 met the inclusion criteria, 6 cohort and 1 randomized clinical trial. Most of the studies preferred platelet rich fibrin (PRF) and only one used platelet rich plasma (PRP) in MRONJ treatment. MRONJ stage, patients mean age, drug therapy, follow-up and success rate were analysed in all the studies. Five studies also named how MRONJ initiated and 4 studies mentioned duration of drug intake before developing MRONJ. Conclusion. The published data is not sufficient to confirm a specific treatment protocol although the published results are promising. More prospective randomized controlled clinical trials are required in order to evaluate the effectiveness of APCs for treatment of MRONJ.
-
6دورية أكاديمية
المؤلفون: Pranevičius, Robertas, Morkūnaitė, Kristina, Unikas, Ramūnas
المصدر: Lietuvos bendrosios praktikos gydytojas, Kaunas : Vitae Litera, 2020, t. 24, Nr. 1, p. 27-33 ; ISSN 1392-3218
مصطلحات موضوعية: Atrial fibrillation, drug therapy, surgery, Anticoagulants, therapeutic use, adverse effects, Hemorrhage, chemically induced, Stroke, prevention&control, Warfarin, administration&dosage, Adninistration, oral, Atrial appendage, info:eu-repo/classification/udc/616.12-008.313.2
الوصف: Atrial fibrillation (PV) remains the most common arrhythmia that is encountered in clinical practice. Patients with this arrhythmia have a significantly higher rate of stroke, which is why they are usually prescribed vitamin K antagonists (warfarin) or direct oral anticoagulants (DOACs). To date, patients with severe conditions who have co-pathologies or a history of bleeding, being unable to take warfarin resulting in reduced doses of DOACs, it has become increasingly difficult to balance the therapeutic benefit with the lowest risk of new complications for the patient. The alternative for these patients is left atrial appendage (LAA) closure, which was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin, for patients with nonvalvular atrial fibrillation. Since recently there was no clinical indication for LAA closure of patient, complications and delayed outcome after closure implantation were not clearly defined and evaluated. After a series of clinical trials (PREVAIL, PROTECT-AF) particularly LAA closure as therapy is introduced as a safe general clinical practice. Clinical results showed that the procedure with Watchman occluder device provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality. Moreover, the LAA closure group results have shown reduced risk of stroke, decreased bleeding and risk of death. Considering the world-wide practice first successful procedure in the Hospital of Lithuanian University of Health Sciences Kauno klinikos was performed. Conclusion. Based on global post-FDA approval clinical experience of LAA closure, procedural success was high and complication rates were low.
-
7دورية أكاديمية
المؤلفون: Sveikata, Audrius, Liutkauskienė, Sigita, Juozaitytė, Elona, Characiejus, Dainius, Tamošaitytė, Laimutė, Šeštakauskas, Kastytis
المصدر: Medicina, Kaunas : Lietuvos sveikatos mokslų universitetas, 2011, t. 47, Nr. 8, p. 428-433 ; ISSN 1010-660X
مصطلحات موضوعية: Breast neoplasms, Drug therapy, Neutropenia, Chemically induced, Granulocyte colony-stimulating factor, Therapeutic use, Multicenter studies as topic, Clinical trials, phase IV as Topic, info:eu-repo/classification/udc/618.19-006.6
الوصف: The primary objective of this open-label, two chemotherapy arm, phase 4 study was to evaluate the safety and efficacy of new developed recombinant granulocyte colony-stimulating factor (rG-CSF) used to prevent neutropenia-related complications in patients with metastatic breast cancer treated with docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) or docetaxel (100 mg/m2) alone. Material and Methods. A total of 50 patients who were treated with a maximum of 6 cycles of either docetaxel-doxorubicin (36 patients) or docetaxel alone (14 patients) every 21 days were recruited from 3 centers in Lithuania. All the patients received study medication rG-CSF at a dosage of 5 μg/kg per day (Sicor Biotech UAB, Teva Group) from day 2 of each cycle and continued for minimum 5 days or until absolute neutrophil count reached ≥1.5×109/L. Results. A total of 611 adverse events were reported. Most of them were related to myelotoxic chemotherapy. Two patients withdrew due to adverse events (neuropathy and bone pain). One patient died possibly because of pulmonary thromboembolism. The most frequently reported adverse events related to study drug in the docetaxel-doxorubicin group and docetaxel groups were leukocytosis (22% and 21%, respectively), bone pain (19% and 21%, respectively), and headache (8% and 14%, respectively). The incidence of grade 4 neutropenia in both the groups was 47% and 29%, respectively, in all cycles and 42% and 21%, respectively, in cycle 1. The incidence of febrile neutropenia was 8% in cycle 1 and 14% across all cycles. The mean duration of febrile neutropenia was 2.1 days (SD, 1.9) in cycle 1 and 2.14 days (SD 2.0) across all cycles in both the treatment groups. Conclusion. [.].
وصف الملف: application/pdf
العلاقة: http://lsmu.oai.elaba.lt/documents/5452806.pdfTest; http://lsmu.lvb.lt/LSMU:ELABAPDB5452806&prefLang=en_USTest
-
8دورية أكاديمية
المؤلفون: Liutkauskienė, Sigita, Sveikata, Audrius, Juozaitytė, Elona, Characiejus, Dainius, Juodžbalienė, Edita Bronė, Kregždytė, Rima, Fokas, Vidmantas
المصدر: Medicina, Kaunas : Kauno medicinos universitetas, 2009, t. 45, Nr. 8, p. 600-606 ; ISSN 1010-660X
مصطلحات موضوعية: Breast neoplasms, Drug therapy, Neutropenia, Chemically induced, Granulocyte colony stimulating factor, Therapeutic use, Antineoplastic agents, Doxorubicin, info:eu-repo/classification/udc/618.19-006.6
الوصف: BACKGROUND: We evaluated efficacy and safety of recombinant granulocyte-colony stimulating factor (rGCSF) used as primary prophylaxis to prevent neutropenia and neutropenia-related complications induced by docetaxel and doxorubicin chemotherapy in patients with metastatic breast cancer. PATIENTS AND METHODS: Three centers in Lithuania enrolled 36 patients who received rGCSF (5 microg/kg/d) on day 2 of each 21-day chemotherapy with docetaxel 75 mg/m(2) and doxorubicin 50 mg/m(2) (AT) starting in the first cycle. Treatment regimen was repeated for up to six cycles. RESULTS: Leukocytosis, bone pain, and headache were the most frequent adverse events, with incidence rates of 22%, 19%, and 8%, respectively. Adverse events were typical for rGCSF in this patient population. Overall incidence rate of febrile neutropenia was 14%. The mean duration of febrile neutropenia episodes across cycles was 2.14 days. Incidence of chemotherapy delay was 2%. There was no reduction in chemotherapy dose due to expected toxicity or side effects. Intravenous antibiotics for the treatment of febrile neutropenia were needed in 19% of cases. Quality-of-life assessment shows a significant improvement in emotional functioning and a significant decrease in pain score. The efficacy profile of rGCSF observed in the present study was comparable with that of other rGCSF products previously described in the published scientific literature. CONCLUSIONS: The primary prophylaxis of neutropenia and its complications by rGCSF was safe and effective for women with metastatic breast cancer who received chemotherapy with docetaxel and doxorubicin.
وصف الملف: application/pdf
العلاقة: http://lsmu.oai.elaba.lt/documents/5265110.pdfTest; http://lsmu.lvb.lt/LSMU:ELABAPDB5265110&prefLang=en_USTest
-
9دورية أكاديمية
المؤلفون: Reingardienė, Dagmara Ona
المصدر: Medicina, 2008, t. 44, Nr. 9, p. 723-732 ; ISSN 1010-660X
مصطلحات موضوعية: Thrombocytopenia, Chemically induced, Heparin, Adverse effects, info:eu-repo/classification/udc/616.155.2
الوصف: In clinical use for over 50 years, heparin is an important and widely used anticoagulant for the prophylaxis or treatment of thromboembolic disease as well as other numerous clinical situations. Ordinarily, heparin prevents clotting and does not affect the platelets, components of the blood that help to form blood clots. However, heparin can also cause heparin-induced thrombocytopenia. Two distinct types of heparininduced thrombocytopenia can occur: nonimmune and immune mediated. Nonimmune heparin-induced thrombocytopenia, which occurs most frequently, is characterized by a mild decrease in the platelet count and is not harmful. The second type, immune-mediated heparin-induced thrombocytopenia, occurs much less frequently but is dangerous. Immune-mediated heparin-induced thrombocytopenia causes much lower platelet count. Paradoxically, despite a very low platelet count, patients who suffer from heparin-induced thrombocytopenia are at risk for arterial or venous thrombosis. In this review article, there are discussed about pathogenesis of heparin-induced thrombocytopenia, other causes of thrombocytopenia, clinical features, laboratory confirmation of diagnosis, and management of patients (direct thrombin inhibitors, other therapies, duration of therapy, and use of oral anticoagulants). Prognosis and prophylaxis of this life-threatening disorder, which can develop from the use of unfractionated or (less commonly) low-molecular-weight heparin, are also discussed.
وصف الملف: application/pdf
العلاقة: http://lsmu.oai.elaba.lt/documents/5226884.pdfTest; http://lsmu.lvb.lt/LSMU:ELABAPDB5226884&prefLang=en_USTest
-
10مؤتمر
المصدر: Respublikinė konferencija "Lėtinio uždegimo odos ligos", skirta Pasaulinei žvynelinės dienai paminėti : konferencijos pranešimų santraukų knyga : Kaunas, 2018 m. spalio 26 d. / Lietuvos sveikatos mokslų universitetas. Vilniaus universitetas [ir. kt.], Kaunas : Lietuvos sveikatos mokslų universiteto Leidybos namai, 2018, Nr. P III.3, p. 25-26 ; ISBN 9789955155690
